following a full submission:
tarlatamab (Imdylltra®) is not recommended for use within NHSScotland.
Indication under review: treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after at least two prior lines of therapy including platinum-based chemotherapy.
In a single-arm, open-label, phase II study in patients with ES-SCLC who had received at least two prior lines of therapy, tarlatamab resulted in an objective response rate of 40%.
The submitting company’s justification of the treatment’s cost in relation to its health benefits was not sufficient and in addition the company did not present a sufficiently robust economic analysis to gain acceptance by SMC.
Medicine details
- Medicine name:
- tarlatamab (Imdylltra)
- SMC ID:
- SMC2816
- Indication:
Treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after at least two prior lines of therapy including platinum-based chemotherapy.
- Pharmaceutical company
- Amgen Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 10 November 2025